Status:
COMPLETED
A Microneurography (MNG) Study of VX-150 in Healthy Participants
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Conditions:
Pain
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine if C fiber conduction is impacted by NAV1.8 modulation.
Detailed Description
This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable ...
Eligibility Criteria
Inclusion
- Key
- Body mass index (BMI) of 18.0 to 30.0 kilogram per meter square (kg/m\^2)
- A total body weight \>50 kg
- Key
Exclusion
- Participants who have any 1 of the following criteria in the foot/ankle in which MNG will be performed:
- Injection of local anesthetics or steroids within 35 days prior to randomization
- Unsuitable anatomy of the superficial peroneal nerve (i.e., nerve cannot be seen or palpated at the dorsum of the foot/ankle)
- Infection, disease (dermatologic or vascular), ongoing pain, or recent trauma or surgery that may affect study assessments
- History of febrile illness within 14 days before study drug dosing
- Any condition possibly affecting drug absorption
- Participants with Type 1 or Type 2 diabetes mellitus
- Any dermatological (generalized) or autoimmune disease that may affect C-nociceptor excitability
- Other protocol defined Inclusion/Exclusion criteria may apply.
Key Trial Info
Start Date :
June 16 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 23 2022
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT05418712
Start Date
June 16 2022
End Date
September 23 2022
Last Update
October 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
MAC Clinical Research
Manchester, United Kingdom